PT  - JOURNAL ARTICLE
AU  - Wu, Zhenquan
AU  - Zhao, Jinfeng
AU  - Lam, Waiching
AU  - Yang, Mingmin
AU  - Chen, Lu
AU  - Huang, Xuelin
AU  - Wei, Meirong
AU  - Yang, Hui
AU  - Lv, Fan
AU  - Zhang, Fuyan
AU  - Zeng, Jian
AU  - Zhang, Guo-Ming
TI  - Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial
AID  - 10.1136/bjophthalmol-2020-318026
DP  - 2022 Jul 01
TA  - British Journal of Ophthalmology
PG  - 975--979
VI  - 106
IP  - 7
4099  - http://bjo.bmj.com/content/106/7/975.short
4100  - http://bjo.bmj.com/content/106/7/975.full
SO  - Br J Ophthalmol2022 Jul 01; 106
AB  - Purpose To compare the recurrence rate and surgical complications of retinopathy of prematurity (ROP) between patients treated with intravitreal injection of conbercept (IVC) and intravitreal injection of ranibizumab (IVR) within 6 months.Methods A multicentral prospective, randomised controlled trial was applied from May 2017 to February 2019 for the infants diagnosed as aggressive posterior-ROP, zone I or posterior zone II treatment-requiring ROP by binocular indirect ophthalmoscope and RetCam3. These infants were assigned to randomly receive either intravitreal injection of 0.25 mg conbercept or 0.25 mg ranibizumab. The recurrence rate, fundus fluorescence angiography (FFA) and surgical complications were examined during the follow-up period of 6 months. Recurrent eyes were retreated by laser or another intravitreal injection within the 72 hours.Results A total of 30 infant patients (60 eyes) underwent IVC and 30 patients (60 eyes) underwent IVR. A total of 10 eyes (16.67%) in the IVC group and 14 eyes (23.34%) in the IVR group developed recurrence. There was no significant statistical difference in the recurrence rate between the two groups (χ2=0.83, p=0.36). The postmenstrual age (PMA) at first injection was (34.60±3.47) weeks in IVC and (35.14±1.76) in IVR group. In recurrent cases, the mean PMA at second treatment were (43.31±3.85) and (43.43±3.89) weeks in the IVC and IVR group, respectively. The period between two treatments was (8.71±6.62) for the IVC and (8.29±2.56) weeks for the IVR group. All these results showed no significant statistical difference between these two groups. The fluorescein leakage were observed in the eyes of recurrent infants by FFA. There were no other complications in the two groups except for complicated cataract in three eyes.Conclusion Both IVC and IVR are effective therapies for the treatment of ROP. Conbercept is a new option for treating ROP.Data are available in a public, open access repository. Data are available on reasonable request.